Active, not recruitingPhase 2NCT04584983
Bilirubin Neurotoxicity (BN) and Neurodevelopmental Impairment (NDI) in Extremely Preterm (EP) Infants: Avoidable by Reducing the Usual Intravenous Lipid (UL) Administration
Studying Bilirubin encephalopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- The University of Texas Health Science Center, Houston
- Principal Investigator
- Lindsay F Holzapfel, MD, MS, MD, MSThe University of Texas Health Science Center, Houston
- Intervention
- usual prescribed intralipid (UL) regimen(drug)
- Enrollment
- 134 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- The University of Texas Health Science Center at Houston, Houston, Texas, United States
Collaborators
National Center for Advancing Translational Sciences (NCATS)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04584983 on ClinicalTrials.gov